CL2024001043A1 - Formas de sal de un receptor del componente c5a del complemento - Google Patents
Formas de sal de un receptor del componente c5a del complementoInfo
- Publication number
- CL2024001043A1 CL2024001043A1 CL2024001043A CL2024001043A CL2024001043A1 CL 2024001043 A1 CL2024001043 A1 CL 2024001043A1 CL 2024001043 A CL2024001043 A CL 2024001043A CL 2024001043 A CL2024001043 A CL 2024001043A CL 2024001043 A1 CL2024001043 A1 CL 2024001043A1
- Authority
- CL
- Chile
- Prior art keywords
- salt forms
- receptor
- complement component
- compound
- complement
- Prior art date
Links
- 150000003839 salts Chemical group 0.000 title abstract 3
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 title 1
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 title 1
- 230000000295 complement effect Effects 0.000 title 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 2
- 108010078546 Complement C5a Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
Abstract
En el presente documento se proporcionan formas de sal de un receptor del componente 5a del complemento que tiene la fórmula del Compuesto 1. En el presente documento también se proporcionan composiciones farmacéuticas y los métodos de tratamiento que usan las formas de sales del Compuesto 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962932658P | 2019-11-08 | 2019-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001043A1 true CL2024001043A1 (es) | 2024-10-18 |
Family
ID=75846470
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001183A CL2022001183A1 (es) | 2019-11-08 | 2022-05-04 | Formas de sal de un receptor del componente c5a del complemento |
| CL2024001045A CL2024001045A1 (es) | 2019-11-08 | 2024-04-09 | Formas de sal de un receptor del componente c5a del complemento |
| CL2024001042A CL2024001042A1 (es) | 2019-11-08 | 2024-04-09 | Formas de sal de un receptor del componente c5a del complemento |
| CL2024001043A CL2024001043A1 (es) | 2019-11-08 | 2024-04-09 | Formas de sal de un receptor del componente c5a del complemento |
| CL2024001044A CL2024001044A1 (es) | 2019-11-08 | 2024-04-09 | Formas de sal de un receptor del componente c5a del complemento |
| CL2024001047A CL2024001047A1 (es) | 2019-11-08 | 2024-04-09 | Formas de sal de un receptor del componente c5a del complemento |
| CL2024001046A CL2024001046A1 (es) | 2019-11-08 | 2024-04-09 | Formas de sal de un receptor del componente c5a del complemento |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001183A CL2022001183A1 (es) | 2019-11-08 | 2022-05-04 | Formas de sal de un receptor del componente c5a del complemento |
| CL2024001045A CL2024001045A1 (es) | 2019-11-08 | 2024-04-09 | Formas de sal de un receptor del componente c5a del complemento |
| CL2024001042A CL2024001042A1 (es) | 2019-11-08 | 2024-04-09 | Formas de sal de un receptor del componente c5a del complemento |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001044A CL2024001044A1 (es) | 2019-11-08 | 2024-04-09 | Formas de sal de un receptor del componente c5a del complemento |
| CL2024001047A CL2024001047A1 (es) | 2019-11-08 | 2024-04-09 | Formas de sal de un receptor del componente c5a del complemento |
| CL2024001046A CL2024001046A1 (es) | 2019-11-08 | 2024-04-09 | Formas de sal de un receptor del componente c5a del complemento |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11427541B2 (es) |
| EP (1) | EP4054541B1 (es) |
| JP (2) | JP2022553835A (es) |
| KR (1) | KR20220099989A (es) |
| CN (7) | CN118908879A (es) |
| AU (1) | AU2020380367B2 (es) |
| BR (1) | BR112022008183A2 (es) |
| CA (6) | CA3236258A1 (es) |
| CL (7) | CL2022001183A1 (es) |
| ES (1) | ES3072406T3 (es) |
| IL (1) | IL292371A (es) |
| MX (1) | MX429153B (es) |
| TW (1) | TWI900501B (es) |
| WO (1) | WO2021092295A1 (es) |
| ZA (1) | ZA202204442B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220098754A (ko) | 2019-11-08 | 2022-07-12 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 비정질 형태 |
| AU2020378061A1 (en) * | 2019-11-08 | 2022-05-26 | Chemocentryx, Inc. | Free base crystalline form of a complement component C5a receptor |
| WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
| WO2025227089A1 (en) | 2024-04-26 | 2025-10-30 | Amgen Inc. | Solid state forms of (2r,3s)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-n-(4-methyl-3-(trifluoromethyl)phenyl)piperidine-3-carboxamide |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| CN101031548B (zh) | 2004-09-27 | 2011-04-06 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备 |
| JP5819730B2 (ja) | 2008-12-22 | 2015-11-24 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト |
| US20110275639A1 (en) * | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| JP6898229B6 (ja) * | 2014-09-29 | 2021-07-28 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト製造における方法及び中間体 |
| KR20200109297A (ko) | 2017-10-31 | 2020-09-22 | 케모센트릭스, 인크. | 소변 sCD163의 C5aR 억제제 감소 |
| JP2021527062A (ja) | 2018-06-07 | 2021-10-11 | ケモセントリックス，インコーポレイティド | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
| BR112021017756A2 (pt) * | 2019-03-11 | 2021-11-16 | Inflarx Gmbh | Piperidinila bicíclica fundida e compostos relacionados como moduladores do receptor c5a |
| AU2020378061A1 (en) | 2019-11-08 | 2022-05-26 | Chemocentryx, Inc. | Free base crystalline form of a complement component C5a receptor |
| KR20220098754A (ko) | 2019-11-08 | 2022-07-12 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 비정질 형태 |
-
2020
- 2020-11-06 AU AU2020380367A patent/AU2020380367B2/en active Active
- 2020-11-06 CN CN202410992468.7A patent/CN118908879A/zh active Pending
- 2020-11-06 CN CN202080077957.XA patent/CN114867473A/zh active Pending
- 2020-11-06 CA CA3236258A patent/CA3236258A1/en active Pending
- 2020-11-06 US US17/091,044 patent/US11427541B2/en active Active
- 2020-11-06 MX MX2022005522A patent/MX429153B/es unknown
- 2020-11-06 CA CA3155950A patent/CA3155950C/en active Active
- 2020-11-06 BR BR112022008183A patent/BR112022008183A2/pt unknown
- 2020-11-06 CN CN202410992484.6A patent/CN118908882A/zh active Pending
- 2020-11-06 CN CN202410992465.3A patent/CN118908878A/zh active Pending
- 2020-11-06 CA CA3236249A patent/CA3236249A1/en active Pending
- 2020-11-06 CN CN202410992494.XA patent/CN118908883A/zh active Pending
- 2020-11-06 CA CA3236253A patent/CA3236253A1/en active Pending
- 2020-11-06 JP JP2022525932A patent/JP2022553835A/ja active Pending
- 2020-11-06 TW TW109138822A patent/TWI900501B/zh active
- 2020-11-06 CN CN202410992477.6A patent/CN118908881A/zh active Pending
- 2020-11-06 WO PCT/US2020/059291 patent/WO2021092295A1/en not_active Ceased
- 2020-11-06 ES ES20883776T patent/ES3072406T3/es active Active
- 2020-11-06 CA CA3235574A patent/CA3235574A1/en active Pending
- 2020-11-06 EP EP20883776.5A patent/EP4054541B1/en active Active
- 2020-11-06 CA CA3236256A patent/CA3236256A1/en active Pending
- 2020-11-06 IL IL292371A patent/IL292371A/en unknown
- 2020-11-06 CN CN202410992469.1A patent/CN118908880A/zh active Pending
- 2020-11-06 KR KR1020227019006A patent/KR20220099989A/ko not_active Ceased
-
2022
- 2022-04-20 ZA ZA2022/04442A patent/ZA202204442B/en unknown
- 2022-05-04 CL CL2022001183A patent/CL2022001183A1/es unknown
-
2024
- 2024-04-09 CL CL2024001045A patent/CL2024001045A1/es unknown
- 2024-04-09 CL CL2024001042A patent/CL2024001042A1/es unknown
- 2024-04-09 CL CL2024001043A patent/CL2024001043A1/es unknown
- 2024-04-09 CL CL2024001044A patent/CL2024001044A1/es unknown
- 2024-04-09 CL CL2024001047A patent/CL2024001047A1/es unknown
- 2024-04-09 CL CL2024001046A patent/CL2024001046A1/es unknown
-
2025
- 2025-07-25 JP JP2025124712A patent/JP2025170250A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001046A1 (es) | Formas de sal de un receptor del componente c5a del complemento | |
| CL2021001228A1 (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
| CL2018001899A1 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| CL2020000215A1 (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp. | |
| MX2020006460A (es) | Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar. | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| SV2018005633A (es) | Derivados de heteroarilo como inhibidores de parp | |
| MX2020007947A (es) | Inhibidores de erbb/btk. | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| MX2018012541A (es) | Inhibidores de bromodominios. | |
| MX386547B (es) | Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer. | |
| MX378806B (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas. | |
| CO2019005552A2 (es) | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos | |
| CO2018012485A2 (es) | Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos | |
| BR112019003577A2 (pt) | métodos de tratamento da semente e produtos resultantes | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| AR130617A1 (es) | Compuesto de anillo fusionado y medicamento que lo comprende | |
| UY36677A (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| EA202191519A1 (ru) | Модуляторы trex1 | |
| CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| CL2020000944A1 (es) | Compuestos bicíclicos y métodos de utilización de los mismos. | |
| MX2021003945A (es) | Compuestos de indolinona para uso como inhibidores de map4k1. | |
| CL2019001041A1 (es) | Compuestos terapéuticos y métodos para utilizarlos. | |
| MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). |